Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients
Primary Purpose
Acute Otitis Media
Status
Completed
Phase
Phase 3
Locations
Spain
Study Type
Interventional
Intervention
DF289
DF277
DF289 plus DF277
Sponsored by
About this trial
This is an interventional treatment trial for Acute Otitis Media focused on measuring with tubes
Eligibility Criteria
Inclusion Criteria:
- 6 months to 12 years
- ear tube in the ear which will be treated
- otorrhea for 3 weeks or less
- moderate or severe otorrhea
Exclusion Criteria:
- other ear diseases
Sites / Locations
- Laboratorios SALVAT S.A.
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Experimental
Arm Label
DF289
DF277
DF289 plus DF277
Arm Description
Ear drops
Ear drops
Ear drops
Outcomes
Primary Outcome Measures
Time to Cessation of Otorrhea
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01404611
Brief Title
Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients
Official Title
A Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution Compared to DF289 Otic Solution and to DF277 Otic Solution in the Treatment of Acute Otitis Media With Tympanostomy Tubes (AOMT) in Pediatric Patients
Study Type
Interventional
2. Study Status
Record Verification Date
October 2015
Overall Recruitment Status
Completed
Study Start Date
June 2011 (undefined)
Primary Completion Date
May 2013 (Actual)
Study Completion Date
June 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Salvat
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine if a combination of an antibiotic plus a corticosteroid is safe and effective in treating middle ear infections in children with ear tubes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Otitis Media
Keywords
with tubes
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
331 (Actual)
8. Arms, Groups, and Interventions
Arm Title
DF289
Arm Type
Active Comparator
Arm Description
Ear drops
Arm Title
DF277
Arm Type
Active Comparator
Arm Description
Ear drops
Arm Title
DF289 plus DF277
Arm Type
Experimental
Arm Description
Ear drops
Intervention Type
Drug
Intervention Name(s)
DF289
Intervention Description
Ear drops
Intervention Type
Drug
Intervention Name(s)
DF277
Intervention Description
Ear drops
Intervention Type
Drug
Intervention Name(s)
DF289 plus DF277
Intervention Description
Ear drops
Primary Outcome Measure Information:
Title
Time to Cessation of Otorrhea
Time Frame
From baseline until the end of the study (up to 22 days)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
6 months to 12 years
ear tube in the ear which will be treated
otorrhea for 3 weeks or less
moderate or severe otorrhea
Exclusion Criteria:
other ear diseases
Facility Information:
Facility Name
Laboratorios SALVAT S.A.
City
Esplugues de Llobregat
State/Province
Barcelona
ZIP/Postal Code
08950
Country
Spain
12. IPD Sharing Statement
Citations:
PubMed Identifier
28006041
Citation
Spektor Z, Pumarola F, Ismail K, Lanier B, Hussain I, Ansley J, Butehorn HF 3rd, Esterhuizen K, Byers J, Douglis F, Lansford B, Hernandez FJ. Efficacy and Safety of Ciprofloxacin Plus Fluocinolone in Otitis Media With Tympanostomy Tubes in Pediatric Patients: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2017 Apr 1;143(4):341-349. doi: 10.1001/jamaoto.2016.3537.
Results Reference
derived
Learn more about this trial
Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients
We'll reach out to this number within 24 hrs